AlgiPharma AS is a clinical stage biopharmaceutical company focusing on respiratory diseases and other conditions caused by microbial infections and biofilms.

AlgiPharma’s technology is based on alginate oligosaccharides with defined structures.

Within the SFI-IB, AlgiPharma aims to further develop sustainable and robust production processes for their alginate- based technology. The main field of innovations will be new products and production technology for bioactive functionalized biopolymers and oligomers, including engineering of microbial strains for biopolymer production and processing and upgrading, industrial enzymes (for functionalisation and upgrading of biopolymers).

The focus of the SFI-IB, access to infrastructure and competence, and synergies with other SFI-IB partners will add value to AlgiPharma’s development programs.

AlgiPharma AS is an industry partner in the project.